Literature DB >> 36204172

Psychiatric Uses of Gabapentin.

Jon C Martin1, Danielle Gainer2.   

Abstract

Objective: This article reviews evidence-based psychiatric uses of gabapentin, along with associated risks. Method of Research: An extensive literature review was conducted, primarily of articles searchable in PubMed, relating to psychiatric uses, safety, and adverse effects of gabapentin.
Results: Evidence supports gabapentin as a treatment for alcohol withdrawal and alcohol use disorder. There is sufficient evidence to consider gabapentin as a third-line treatment for social anxiety disorder and severe panic disorder. Evidence does not support the use of gabapentin for bipolar disorder, major depressive disorder (MDD), posttraumatic stress disorder (PTSD), obsessive compulsive disorder (OCD), stimulant use disorder, or opioid withdrawal. Risks of gabapentin use are highest among those with a history of a substance use disorder and those concurrently taking opioids.
Conclusion: While gabapentin has a place in psychiatry for a select few indications, the literature does not support its use for many studied diagnoses.
Copyright © 2022. Matrix Medical Communications. All rights reserved.

Entities:  

Keywords:  Gabapentin; alcohol use disorder; alcohol withdrawal; neurontin; opioids

Year:  2022        PMID: 36204172      PMCID: PMC9507147     

Source DB:  PubMed          Journal:  Innov Clin Neurosci        ISSN: 2158-8333


  49 in total

1.  Pharmacotherapy to prevent PTSD: Results from a randomized controlled proof-of-concept trial in physically injured patients.

Authors:  Murray B Stein; Carol Kerridge; Joel E Dimsdale; David B Hoyt
Journal:  J Trauma Stress       Date:  2007-12

2.  Smoked cocaine self-administration by humans is not reduced by large gabapentin maintenance doses.

Authors:  Carl L Hart; Margaret Haney; Eric D Collins; Eric Rubin; Richard W Foltin
Journal:  Drug Alcohol Depend       Date:  2006-08-01       Impact factor: 4.492

3.  Importance of gabapentin dose in treatment of opioid withdrawal.

Authors:  Mehrdad Salehi; Gholam Reza Kheirabadi; Mohammad Reza Maracy; Mansour Ranjkesh
Journal:  J Clin Psychopharmacol       Date:  2011-10       Impact factor: 3.153

4.  Double-blind placebo-controlled evaluation of the PROMETA™ protocol for methamphetamine dependence.

Authors:  Walter Ling; Steven Shoptaw; Maureen Hillhouse; Michelle A Bholat; Charles Charuvastra; Keith Heinzerling; David Chim; Jeffrey Annon; Patrick T Dowling; Geetha Doraimani
Journal:  Addiction       Date:  2011-11-15       Impact factor: 6.526

5.  Placebo-controlled study of gabapentin treatment of panic disorder.

Authors:  A C Pande; M H Pollack; J Crockatt; M Greiner; G Chouinard; R B Lydiard; C B Taylor; S R Dager; T Shiovitz
Journal:  J Clin Psychopharmacol       Date:  2000-08       Impact factor: 3.153

6.  All-Cause and Drug-Related Medical Events Associated with Overuse of Gabapentin and/or Opioid Medications: A Retrospective Cohort Analysis of a Commercially Insured US Population.

Authors:  Alyssa M Peckham; Kathleen A Fairman; David A Sclar
Journal:  Drug Saf       Date:  2018-02       Impact factor: 5.606

7.  Efficacy of Gabapentin for the Treatment of Alcohol Use Disorder in Patients With Alcohol Withdrawal Symptoms: A Randomized Clinical Trial.

Authors:  Raymond F Anton; Patricia Latham; Konstantin Voronin; Sarah Book; Michaela Hoffman; James Prisciandaro; Emily Bristol
Journal:  JAMA Intern Med       Date:  2020-05-01       Impact factor: 21.873

Review 8.  Gabapentin misuse, abuse and diversion: a systematic review.

Authors:  Rachel V Smith; Jennifer R Havens; Sharon L Walsh
Journal:  Addiction       Date:  2016-03-18       Impact factor: 6.526

Review 9.  How addictive are gabapentin and pregabalin? A systematic review.

Authors:  U Bonnet; N Scherbaum
Journal:  Eur Neuropsychopharmacol       Date:  2017-10-05       Impact factor: 4.600

10.  Gabapentin reduces alcohol consumption and craving: a randomized, double-blind, placebo-controlled trial.

Authors:  Fernando A Furieri; Ester M Nakamura-Palacios
Journal:  J Clin Psychiatry       Date:  2007-11       Impact factor: 4.384

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.